J&J bows out of RSV vac­cine race, end­ing PhI­II study and ced­ing to Pfiz­er, GSK

John­son & John­son an­nounced Wednes­day morn­ing it is end­ing de­vel­op­ment of its adult RSV vac­cine that was in the mid­dle of a 27,200-pa­tient tri­al, giv­ing up a big slice of what’s ex­pect­ed to be the next multi­bil­lion-dol­lar phar­ma mar­ket.

The de­ci­sion came down to the shift­ing RSV “com­pet­i­tive land­scape,” a com­pa­ny spokesper­son tells End­points News, adding the “breadth of op­tions” was much dif­fer­ent than when J&J first start­ed its piv­otal study. The spokesper­son de­clined to com­ment on the Phase III da­ta, say­ing on­ly the shot is un­der­go­ing an “on­go­ing as­sess­ment.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN